Expanded phase 1 study of ABL001, a potent, allosteric inhibitor of BCR-ABL, reveals significant and durable responses in patients with CML-chronic phase with failure of prior TKI therapy Meeting Abstract
| Authors: | Hughes, T. P.; Goh, Y. T.; Ottmann, O. G.; Minami, H.; Rea, D.; Lang, F.; Mauro, M. J.; DeAngelo, D. J.; Talpaz, M.; Hochhaus, A.; Breccia, M.; Cortes, J. E.; Heinrich, M. C.; Janssen, J.; Steegmann, J. L.; Mahon, F. X.; Duan, R.; Iyer, V.; Hynds, D.; Vanasse, G. J.; Kim, D. W. |
| Abstract Title: | Expanded phase 1 study of ABL001, a potent, allosteric inhibitor of BCR-ABL, reveals significant and durable responses in patients with CML-chronic phase with failure of prior TKI therapy |
| Meeting Title: | 58th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 128 |
| Issue: | 22 |
| Meeting Dates: | 2016 Dec 3-6 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2016-12-02 |
| Language: | English |
| ACCESSION: | WOS:000394446804098 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V128.22.625.625 |
| Notes: | Meeting Abstract: 625 -- Source: Wos |
